Development of paediatric medicines: Concepts and principles

Handbook of Experimental Pharmacology

Volumn 205, Issue , 2011, Pages 111-124

  Rose, Klaus ^a   Pasqua, Oscar Della ^b,c  

^a Klausrose Consulting   (Switzerland)

^b LEIDEN UNIVERSITY   (Netherlands)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Historical context of paediatric drug development; Incentives for paediatric clinical research; Medicines for children; Neglected diseases; Paediatric drug development; Priorities in paediatric drug development; Public health; Regulatory authorities

Indexed keywords

ARTICLE; CLINICAL DEVELOPMENT PLAN; DRUG EFFICACY; DRUG INDUSTRY; DRUG LABELING; DRUG LEGISLATION; DRUG MANUFACTURE; DRUG SAFETY; DRUG UTILIZATION; FOOD AND DRUG ADMINISTRATION; GOVERNMENT REGULATION; HEALTH CARE NEED; HEALTH CARE POLICY; HUMAN; MEDICAL DECISION MAKING; MEDICAL INFORMATION; MEDICAL PRACTICE; OFF LABEL DRUG USE; PEDIATRIC MEDICINE; PEDIATRICS; PERSONALIZED MEDICINE; PHARMACEUTICAL CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUBLIC HEALTH; PUBLIC-PRIVATE PARTNERSHIP; RETROSPECTIVE STUDY; REWARD;

CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; DRUG EVALUATION; EUROPE; HEALTH POLICY; HUMAN DEVELOPMENT; HUMANS; OFF-LABEL USE; PATENTS AS TOPIC; PEDIATRICS; PHARMACOLOGICAL PHENOMENA; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 80054949958     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/978-3-642-20195-0_5     Document Type: Article

References (15)

1. Cella M, Knibbe C, Danhof M, Della Pasqua O (2010) What is the right dose for children? Br J Clin Pharmacol 70:597-603. doi:10.1111/j.1365-2125.2009. 03591.x
2. DNDi (Drugs for Neglected Diseases Initiative) (2010) http://www.dndi.org. Accessed 14 Oct 2010
3. European Medicines Agency (2010) http://www.ema.europa.eu. Accessed 14 Oct 2010
4. FDA (Food and Drug Administration) (2010) http://www.fda.gov. Accessed 14 Oct 2010
5. FDAAA (FDA Amendment Acts) (2010) http://www.fda.gov/ RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/ SignificantAmendmentstotheFDCAct/FoodandDrugAdministrationAmendmentsActof2007/ default.htm. Accessed 14 Oct 2010
6. Gates Foundation (2010) http://www.gatesfoundation.org. Accessed 14 Oct 2010
7. Hilts PJ (2003) Protecting America's health. Alfred A. Knopf, New York
8. ICH (2010) International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use. http://www.ich.org. Accessed 14 Oct 2010
9. ICH E11 (2010) ICH tripartite guideline: Clinical investigation of medicinal products in the pediatric population. http://www.ich.org/LOB/media/ MEDIA487.pdf. Accessed 14 Oct 2010
10. MMV (Medicines for Malaria Venture) (2010) http://www.mmv.org. Accessed 14 Oct 2010
11. Rose K, van den Anker J (eds) (2010) Guide to paediatric drug development and clinical research. Karger, Basel, Switzerland, http://content.karger.com/ ProdukteDB/produkte.asp?Aktion=showproducts&searchWhat=books&ProduktNr= 253804. Accessed 14 Oct 2010. ISBN 978- 3-8055-9362-5; e-ISBN: 978-3-8055-9363-2
12. Stoetter H (2007) Paediatric drug development: Historical background of regulatory initiatives. In: Rose K, van den Anker JN (eds) Guide to paediatric clinical research. Karger, Basel, pp 25-32
13. Taussig HB (1962) A study of the German outbreak of phocomelia. JAMA 180(32):1106-1114
14. Wax P (1995) Elixirs, diluents, and the passage of the 1938 Federal Food, Drug and Cosmetic Act. Ann Intern Med 122:456-461
15. WHO (2010) http://www.who.int. Accessed 14 Oct 2010